13 June, 2008
Sanofi has alleged infringement of U.S. 4,661,491 patent for Method of Use of Uroxatral, used to treat an enlarged prostate gland which expires in early 2011 and is seeking to have injuction for low cost generic Uroxatral
There is yet another composition patent U.S. 6,149,940 listed in OB, which claims a tablet with controlled release of alfuzosin hydrochloride which expires in second half of 2017.
For details refer the link on Bloomberg.com by Phil Milford by clicking on the title
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment